IL308782A - Antibodies - Google Patents

Antibodies

Info

Publication number
IL308782A
IL308782A IL308782A IL30878223A IL308782A IL 308782 A IL308782 A IL 308782A IL 308782 A IL308782 A IL 308782A IL 30878223 A IL30878223 A IL 30878223A IL 308782 A IL308782 A IL 308782A
Authority
IL
Israel
Prior art keywords
antibodies
Prior art date
Application number
IL308782A
Other languages
English (en)
Hebrew (he)
Inventor
Graham Ogg
Clare Hardman
Yi-Ling Chen
Original Assignee
Univ Oxford Innovation Ltd
Graham Ogg
Clare Hardman
Chen yi ling
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2107517.1A external-priority patent/GB202107517D0/en
Priority claimed from GBGB2116709.3A external-priority patent/GB202116709D0/en
Application filed by Univ Oxford Innovation Ltd, Graham Ogg, Clare Hardman, Chen yi ling filed Critical Univ Oxford Innovation Ltd
Publication of IL308782A publication Critical patent/IL308782A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL308782A 2021-05-26 2022-05-20 Antibodies IL308782A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2107517.1A GB202107517D0 (en) 2021-05-26 2021-05-26 Antibodies
GBGB2116709.3A GB202116709D0 (en) 2021-11-19 2021-11-19 Antibodies
PCT/GB2022/051285 WO2022248839A1 (en) 2021-05-26 2022-05-20 Antibodies

Publications (1)

Publication Number Publication Date
IL308782A true IL308782A (en) 2024-01-01

Family

ID=81927992

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308782A IL308782A (en) 2021-05-26 2022-05-20 Antibodies

Country Status (9)

Country Link
US (1) US20240383986A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347045A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024522095A (cg-RX-API-DMAC7.html)
KR (1) KR20240013781A (cg-RX-API-DMAC7.html)
AU (1) AU2022282828A1 (cg-RX-API-DMAC7.html)
CA (1) CA3220308A1 (cg-RX-API-DMAC7.html)
IL (1) IL308782A (cg-RX-API-DMAC7.html)
MX (1) MX2023013979A (cg-RX-API-DMAC7.html)
WO (1) WO2022248839A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025043244A1 (en) * 2023-08-24 2025-02-27 Arizona Board Of Regents On Behalf Of Arizona State University Tandem antigen capture assays for measuring qsox1 isoforms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4712724B2 (ja) * 2003-12-23 2011-06-29 クルセル ホランド ベー ヴェー CD1aに対するヒト結合分子
WO2015042110A1 (en) * 2013-09-20 2015-03-26 Children's Medical Center Corporation Treatment of inflammatory skin disease
EP3696191A1 (en) * 2019-02-14 2020-08-19 Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) Car t-cells for the treatment of cd1a-positive cancer

Also Published As

Publication number Publication date
AU2022282828A1 (en) 2023-12-14
MX2023013979A (es) 2023-12-12
WO2022248839A1 (en) 2022-12-01
KR20240013781A (ko) 2024-01-30
EP4347045A1 (en) 2024-04-10
JP2024522095A (ja) 2024-06-11
AU2022282828A9 (en) 2023-12-21
US20240383986A1 (en) 2024-11-21
CA3220308A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
SI3872091T1 (sl) Protitelesa proti SARS-COV-2
IL289112A (en) Antibodies against tigit
IL308741A (en) Anti-SIRP-alpha antibodies
GB201905150D0 (en) Ant-ige antibodies
PT4214240T (pt) Anticorpos anti-ccr8
GB202105110D0 (en) Anti-CD73 antibodies
IL284584A (en) Anti-tigit antibodies
GB202111905D0 (en) Antibodies
IL300142A (en) Anti-IL13Ralpha2 antibodies
ZA202209699B (en) Novel antibodies
EP4377358A4 (en) NEW ANTI-SIRPA ANTIBODIES
GB202014851D0 (en) SARS-COV-2 antibodies
GB202015115D0 (en) ZIP12 Antibody
GB201917480D0 (en) Antibodies
GB201900732D0 (en) Antibodies
GB202105933D0 (en) Anti-IL1rap antibody
GB202008022D0 (en) Antibodies
IL308100A (en) Antibodies
GB202102227D0 (en) Antibodies
IL289160A (en) Anti-angpt2 antibodies
GB2598698B (en) Affinity-maturated anti-ASICIa antibodies
GB202208773D0 (en) Anti-SARS2-S antibodies
IL307175A (en) IL-38 specific antibodies
GB202116709D0 (en) Antibodies
GB202115824D0 (en) Antibodies